By incorporating these elements into our synthetic biology‐based tumor vaccine, we aim to create a highly responsive and regulated system to enhance the expression of therapeutic genes, including immune mediators, tumor antigens, and PD‐L1 nanobodies, ultimately improving anti‐tumor efficacy in vivo. The gene discussed is CD274; the disease is neoplasm.